Talis Biomedical Corporation announces the appointment of Kim Popovits, former Chairman of the Board, President and Chief Executive Officer of Genomic Health, Inc., to the company’s Board of Directors. Ms. Popovits brings a wealth of expertise and experience in managing organizations, building companies on a global scale and developing innovative diagnostics and medicines.
Kim arrived at Genomic Health in 2002 as President and Chief Operating Officer, before becoming CEO in 2009 and Chairman of the Board in 2012. Under her leadership, Genomic Health became the industry leader in genomic-based diagnostic tests that optimized the treatment of cancer, resulting in an acquisition by Exact Sciences in November 2019.
Prior to joining Genomic Health, Kim held several management roles at Genentech, Inc. including Senior Vice President of Marketing and Sales where she led the commercialization of 14 new therapies in the biotechnology industry. Before Genentech, Kim was at American Critical Care, a Division of American Hospital Supply, a supplier of healthcare products to hospitals.
In addition to her Board position at Talis Biomedical Corporation, Kim is a current member of the Boards of Directors for 10X Genomics, Kiniksa Pharmaceuticals, Ltd. and MyoKardia, Inc., and previously served on the Board of ZS Pharma Inc. She holds a B.A. in Business from Michigan State University.